Kenvue Inc. (KVUE) — Stock Price, Chart & Analysis
Kenvue Inc. (KVUE) is a Consumer Defensive stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $34.31B and a trailing P/E ratio of 20.77. Over the past 52 weeks, KVUE has traded between $14.02 and $20.13. Kenvue Inc. pays a dividend yielding 4.8%. View the live KVUE chart, technical opinion, analyst ratings, fundamentals and latest news below.
Kenvue Inc. (KVUE) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $34.31B |
| P/E ratio (TTM) | 20.77 |
| EPS (TTM) | $0.86 |
| Dividend yield | 4.8% |
| 52-week high | $20.13 |
| 52-week low | $14.02 |
| Beta | 0.43 |
| Avg. volume | 22.96M |
| Sector | Consumer Defensive |
| Industry | Household & Personal Products |
Frequently asked questions about Kenvue Inc. (KVUE)
How much does one share of Kenvue Inc. cost?
As of the latest update, one share of Kenvue Inc. (KVUE) trades at $100 (+0.00% today).
What is Kenvue Inc.'s market cap?
Kenvue Inc. has a market capitalization of approximately $34.31B.
What is Kenvue Inc.'s P/E ratio?
Kenvue Inc. has a trailing price-to-earnings (P/E) ratio of 20.77.
What is Kenvue Inc.'s earnings per share (EPS)?
Kenvue Inc.'s trailing twelve-month EPS is $0.86.
Does Kenvue Inc. pay a dividend?
Yes — Kenvue Inc. pays a dividend with a yield of 4.8% ($0.84 per share annually).
What is Kenvue Inc.'s 52-week trading range?
Over the past year, KVUE has traded between $14.02 and $20.13.
What is the analyst price target for Kenvue Inc.?
The mean analyst price target for Kenvue Inc. is $19.50. This is informational only and not investment advice.
Latest Kenvue Inc. (KVUE) news
- Kenvue Inc's Dividend AnalysisNews · Sep 21, 2026
- Kimberly Clark (KMB) Lines Up Assets for $40 Billion Deal ReviewNews · Sep 18, 2026
- Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?News · Sep 18, 2026
- Should Kenvue’s (KVUE) TYLENOL with Naproxen Launch and Dividend Plan Prompt Investor Reassessment?News · Sep 15, 2026
- Is Kenvue (KVUE) A Bargain Following Its TYLENOL With Naproxen Launch?News · Sep 15, 2026
- Kimberly-Clark Moves to Clear EU Hurdle with Kenvue Asset SalesNews · Sep 15, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live KVUE dashboard…